Safety Study of Abatacept to Treat Refractory Sarcoidosis

Sarcoidosis, Trial of Abatacept in Refractory Disease (STAR). A Prospective Open-Label Trial of Abatacept in Progressive Sarcoidosis

The purpose of this study is to determine how safe and effective Abatacept is in treating patients who have progressive pulmonary sarcoidosis.

Primary Inclusion Criteria:

• Diagnosis of sarcoidosis for at least 1 year with lung disease
• Active disease despite current treatment
• On a stable dose of sarcoidosis treatment with oral steroids, methotrexate, or hydroxychloroquine, for at least 90 days

Primary Exclusion Criteria:

• Previous treatment with Abatacept
• Currently receiving or received within the last 60 days the following: TNFα-inhibitors (infliximab, etanercept, adalimumab)
• Currently receiving or received within the last 30 days the following: cyclosporine, tacrolimus or leflunomide
• Previous treatment of IVIg within the last 6 months
• History of chronic infection that has been active within last 60 days, or herpes zoster within last 6 months, or any infection requiring hospitalization or intravenous medication within last 60 days or oral medication within the last 2 weeks
• History of congestive heart failure
• HIV